ESTRO25: What’s Happening on Day 2
As Day 2 of the ESTRO25 Congress unfolded in Vienna, the energy at the Austria Center only intensified. Building on the momentum of a powerful opening day, delegates immersed themselves in another full schedule of cutting-edge science, clinical innovation, and collaborative exchange.
From the latest in adaptive radiotherapy to real-world insights into patient-centered care, the day was a vivid reflection of ESTRO’s mission to drive excellence across every dimension of radiation oncology. But Day 2 wasn’t just about data and debate—it was also about the moments in between. From impromptu hallway reunions to tweets that reminded us of the human side of oncology, the congress continued to showcase a vibrant, connected community.
In this post, we spotlight must-see moments from Day 2 of ESTRO25— where knowledge met curiosity, and where the professional and personal converged in unforgettable ways.
“Great session at ESTRO25 with 2 excellent chairs..the current Matthias Guckenberger and the future Barbara Jereczek-Fossa ESTRO President!”
“ESTRO25 – Day 2
Late-Breaking Papers
Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321) by Camilla Thellenberg Karlsson.”
“Prof. Murray Brunt presents 10-year FAST-Forward results: 1-week (5-fraction) adjuvant breast RT remains safe and effective long-term. Definitive evidence for a new standard of care.”
“Hypofractionated breast radiotherapy for 1 week vs 3 weeks: 10-year efficacy and late normal tissue effects in the FAST-Forward randomised trial presented by Prof Murray Brunt at ESTRO25
10-year FAST-Forward results.”
“At ESTRO25, Prof. Barbara Jereczek presented salvage SBRT as a promising, underused option for radio-recurrent prostate cancer—offering a non-invasive second chance for cure.
Imaging, biology & tech are key to selecting the best approach.”
“Time to undetectable PSA after salvage RT matters!
Data from 1,091 pts across AIRO-URO centers show that achieving PSA <0.1 ng/mL — within 6 months — strongly predicts both BCR-free and metastasis-free survival post-prostatectomy.”
“10 years outcomes from the HYPO-RT-PC trial confirmed the non-inferiority of ultrahypof. Schedule in terms of failure free survival, with no difference in terms of late GU or GI tox.”
“Wonderful presentation by Sofia Rivera from Gustave Roussy, France regarding the eternal question “to boost or not to boost ? In breast cancer”
1.The lesson from the EORTC boost/ no boost trial is that age is the most important factor. The boost is most beneficial for patients age < 50 years.
2.Boost doubled the risk of fibrosis which increased with age.
3.Assisi think tank meeting 2024: Omit the boost if the estimated reduction in local recurrence at 10 years is less than 3 %.
4.Risk factors for LR: young age, large T, no response to PST, R+, high tumour grade, LVI, extensive intraductal component, triple negative.
5.We need more data. Could we benefit from sophisticated methodology that transforms observational data into structured analyses mimicking traditional randomized controlled trials (RCTs)?”
“How do patients prioritise different aspects of non-operative rectal cancer treatment? We conducted a prospective, multicentre study alongside a clinical trial; asking rectal cancer patients undergoing definitive RT to help us understand treatment preferences.”
“The Royal College of Radiologists team will be at our stand throughout ESTRO25.
Come and find out what we do and how you can get involved – or just for a chat!
We’d love to see you.”
“Radiotherapy beam versus knife for lung cancer at ESTRO25.
Gerry Hanna debating in favor of the beam of course.”
“Great to finally meet my ESTRO Mentor Prof Gustavo Ferrari from Córdoba, Argentina this morning at ESTRO25.
Thanks so much to the Lung Cancer Focus Group for organising this wonderful programme.”
“Birgitte Offersen reports on SKAGEN-1 trial of hypofractionation (40/15 vs 50/25) ESTRO25
- Safe: similar lymphedema
- Effective: similar locoregional and distance recurrence, OS BUT increased breast cancer mortality, across subgroups and without explanation.
Discussions to follow.”
“De-escalation is not omission – it is optimisation. It is not giving less, but giving better, tailored to each patient and supported by evidence”
Icro Meattini, great discussant – ESTRO25 Late Breaking Papers.”
“Really great to meet fellow Peter Mac, Directors of Radiation Oncology – Sandro Porceddu and Prof Trevor Leong at ESTRO25.
So heartening to see Peter Mac Radiation Oncology going from strength to strength under your leadership Sandro.”
“Things that make me happy: Seeing an RT planning & evaluation solution for reirradiation that I’ve helped develop in its (nearly) final version.
Amazing work by the RaySearch team and my CRUK Radnet Leeds Centre colleagues. Probably highlight of ESTRO25 so far for me.”
“First day at ESTRO25! My favorite slide from today: de-escalation is not ommision.”
“We’re delighted to announce the awardees! Huge congratulations to all!
Emmanuel van der Schueren Award: Dirk Verellen, BE & Jens Overgaard Legacy Award: Michael Baumann, DE & the GEC-ESTRO Best Junior Presentation Award: Anne Valkenburg, NL.”
“Transformative innovation through partnership at ESTRO25—visionary research on glioblastoma, spinal cord repair & IGRT presented by Roger Stupp, J. Bloch, G. Courtine & D. Jaffray.
Two of these breakthroughs were born in CHUV”.
“Very effective final slide by CarlottaB from Icro Meattini, Università di Firenze group summarizing results from the BRCABCY collaboration reporting on loco-regional therapy in young BRCA carriers with Breast Cancer.”
“Results of DBCG Skagen trial..lymphedema rates stratified by axillary surgery&RNI are identical to what we reported earlier by
MGH Breast Cancer Lymphedema Research Program.
Another proof that main driving risk for lymphedema is ALND not RNI & hypofrac is safe.”
In the midst of deep dives into proton therapy and radiogenomics, Nina Niu Sanford brought a dose of realness to ESTRO25 with her SOS call:
“Does anyone at ESTRO25 happen to have a Kindle charger I could borrow for a few hours?”
Proof that even at one of the world’s premier oncology congresses, the true emergencies might just be… literary. Paging all radiation oncologists with USB-C cables.
Takeaway: Always pack your charger — and maybe an extra one to make a new friend!
ESTRO25 is officially underway — and we’re bringing you daily highlights, hot takes, and stories straight from the heart of the meeting. Stay tuned!
Don’t miss out on Kicking Off ESTRO25: What’s Happening on Day 1
Written by Md Foorquan Hashmi, MD, Sr. Editor, OncoDaily: India Bureau
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023